Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.14 EUR | +0.71% | +7.53% | -24.20% |
Apr. 23 | Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 29 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
Chart calendar Pharma Mar, S.A.
Upcoming events on Pharma Mar, S.A.
Past events on Pharma Mar, S.A.
2024-04-24 | Q1 2024 Earnings Release (Projected) |
2024-02-29 06:00 am | Q4 2023 Earnings Call |
2024-02-27 | Q4 2023 Earnings Release |
2024-01-07 | JPMorgan Healthcare Conference |
2023-09-08 | European Respiratory Society Congress |
2023-09-05 | National Congress of Virology |
2023-07-28 07:00 am | Q2 2023 Earnings Call |
2023-07-26 | Q2 2023 Earnings Release |
2023-06-22 | Carinthian and Styrian Oncology Symposium |
2023-06-07 | National Congress of the Spanish Society of Pneumology and Thoracic Surgery |
2023-06-06 | Ex-dividend day for final dividend |
2023-06-01 | American Society of Clinical Oncology Conference |
2023-05-31 | Congress of the Spanish Society of Infectious Diseases and Clinical Microbiology |
2023-05-18 | American Thoracic Society International Conference |
2023-05-14 | National Congress of the Spanish Society of Internal Medicine |
2023-05-03 | European Virology Congress |
2023-04-25 | Q1 2023 Earnings Release |
2023-04-19 | AGO Conference |
2023-04-14 | European Congress of Clinical Microbiology & Infectious Diseases |
2023-03-19 | ESMO Sarcoma and Rare Cancers Congress |
Past dividends on Pharma Mar, S.A.
2023-06-06 | Annual 0.5265 EUR |
2022-07-12 | Annual 0.5265 EUR |
2021-04-27 | Annual 0.486 EUR |
2020-06-25 | Annual 0.0324 EUR |
Annual results
Fiscal Period | March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 270 308 -12.45% | 230 186 23.43% | 196 197 -0.12% | 158 157 0.75% | 162 | 196 |
EBITDA Million EUR | Released Forecast Spread | 163 189 -13.85% | 98,0 70,1 39.78% | 50,0 51,8 -3.44% | 2,08 5,48 -61.94% | 14,7 | 86,7 |
EBIT Million EUR | Released Forecast Spread | 156 182 -14.36% | 92,4 63,6 45.43% | 44,1 47,8 -7.84% | -3,83 0,14 -2833.57% | 2,43 | 63,6 |
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 146 187 -22.05% | 95,1 59,2 60.83% | 43,8 56,7 -22.77% | -3,62 -1,45 -149.86% | 3,90 | 35,9 |
Net income Million EUR | Released Forecast Spread | 137 169 -18.65% | 92,9 59,7 55.46% | 49,4 51,5 -4.19% | 1,14 1,38 -17.61% | 1,70 | 56,9 |
EPS EUR | Released Forecast Spread | 7,49 9,12 -17.87% | 5,13 3,16 62.51% | 2,73 2,79 -2.29% | 0,06 0,15 -58.9% | 0,07 | 2,57 |
Announcement Date | 26/02/21 | 28/02/22 | 28/02/23 | 28/02/24 | - | - |
Quarterly results
Fiscal Period | März | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million EUR | Released Forecast Spread | 98,7 102 -3.1% | 85,9 46,5 84.91% | 34,9 30,0 16.46% | 30,2 35,9 -15.97% | 65,1 82,9 -21.43% | 18,7 32,9 -43.06% | 54,9 52,2 5.25% | 34,0 39,1 -13.1% | 46,2 34,2 35.25% | 80,2 69,3 15.8% | 37,5 34,9 7.22% | 40,5 41,5 -2.46% | 33,3 | 44,6 | 38,0 | 36,3 |
EBITDA Million EUR | Released Forecast Spread | 40,6 38,9 4.3% | 44,8 17,3 159.06% | 20,6 22,5 -8.44% | 11,3 14,1 -19.79% | 31,9 31,5 1.39% | 12,6 8,30 51.34% | 5,44 6,90 -21.22% | -1,26 | 5,42 -2,30 335.57% | 4,16 -3,40 222.35% | 1,31 -1,60 181.81% | -3,39 4,10 -182.56% | -3,30 | |||
EBIT Million EUR | Released Forecast Spread | 38,0 35,6 6.61% | 43,4 24,8 74.84% | 19,0 18,9 0.6% | 9,83 11,1 -11.05% | 28,8 30,1 -4.02% | 11,9 7,60 56% | 3,37 9,95 -66.11% | -2,57 3,60 -171.44% | 4,05 -2,33 273.44% | 1,48 -5,05 129.21% | -0,18 0,05 -468% | -5,12 -0,77 -567.56% | -3,47 | 0,30 | -2,00 | -8,60 |
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 12,0 8,70 37.83% | 32,6 29,3 11.31% | 14,0 6,55 113.69% | -2,82 11,7 -124.11% | -3,22 3,60 -189.36% | 4,50 -2,20 304.41% | 1,57 3,50 -55.14% | -6,47 1,30 -597.92% | -1,10 | 0,30 | -2,00 | -8,40 | ||||
Net income Million EUR | Released Forecast Spread | 43,2 35,6 21.36% | 38,2 19,6 94.68% | 22,0 21,2 3.77% | 12,9 8,35 55.07% | 34,9 30,4 15.07% | 8,48 3,40 149.32% | 5,98 6,45 -7.22% | 1,41 3,70 -61.86% | 5,02 -1,00 602.4% | 6,44 -0,15 4390% | 1,52 -0,43 451% | -6,82 -5,50 -23.98% | -3,23 | 0,40 | -2,30 | -9,50 |
EPS EUR | Released Forecast Spread | 0,33 | 0,91 | 0,20 | 0,04 | 0,22 | 0,08 | -0,07 | 0,02 | -0,11 | -0,45 | ||||||
Announcement Date | 29/07/21 | 28/02/22 | 28/04/22 | 27/07/22 | 27/07/22 | 27/10/22 | 28/02/23 | 26/04/23 | 27/07/23 | 27/07/23 | 26/10/23 | 28/02/24 | - | - | - | - |
Today 07:00 am | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-06 | BIOTEST AG: Q1 2024 Earnings Release |
2024-05-06 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-06 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
2024-05-07 02:00 am | BIOGAIA AB: Q1 2024 Earnings Release |
2024-05-07 07:30 am | INTRA-CELLULAR THERAPIES, INC.: Q1 2024 Earnings Release |
2024-05-07 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
2024-05-07 | ZAI LAB LIMITED: Q1 2024 Earnings Release |
2024-05-08 07:55 am | VERICEL CORPORATION: Q1 2024 Earnings Release |
2024-05-08 | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
Past sector events for Pharma Mar, S.A.
2024-05-02 04:05 pm | TWIST BIOSCIENCE CORPORATION: Q2 2024 Earnings Release |
2024-05-02 07:50 am | ARBUTUS BIOPHARMA CORPORATION: Q1 2024 Earnings Release |
2024-05-02 07:30 am | BRIDGEBIO PHARMA, INC.: Q1 2024 Earnings Release |
2024-05-01 | SK BIOSCIENCE CO.,LTD.: Q1 2024 Earnings Release |
2024-04-30 07:00 am | INCYTE CORPORATION: Q1 2024 Earnings Release |
2024-04-29 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q4 2023 Earnings Release |
2024-04-29 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q1 2024 Earnings Release |
2024-04-29 | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED: Q4 2023 Earnings Release |
2024-04-29 05:53 pm | SINOVAC BIOTECH LTD.: Q4 2023 Earnings Release |
2024-04-28 | SHANGHAI OPM BIOSCIENCES CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PHM Stock
- Calendar Pharma Mar, S.A.